Amicus Therapeutics (FOLD) 6.69 $FOLD
Amicus Therapeutics to Highlight Fabry Disease Program at Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
GlobeNewswire - Wed Aug 31, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that 7 posters highlighting its Fabry program will be included in the Society for the Study of Inborn Errors of Metabolism's 2016 SSIEM Annual Symposium to be held September 6-9, 2016 in Rome, Italy.
FOLD: 6.69 (-0.28)
UPDATE -- New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease
GlobeNewswire - Wed Aug 10, 5:05PM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 011 (FACETS) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat in individuals with Fabry disease were published in the August 11 issue of the New England Journal of Medicine (NEJM). A copy of the manuscript can be found here and in the Science & Technology section of the Amicus Therapeutics corporate website at www.amicusrx.com.
FOLD: 6.69 (-0.28)
New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease
GlobeNewswire - Wed Aug 10, 4:18PM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 011 (FACETS) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat in individuals with Fabry disease were published in the June 9 issue of the New England Journal of Medicine (NEJM). A copy of the manuscript can be found here and in the Science & Technology section of the Amicus Therapeutics corporate website at www.amicusrx.com.
FOLD: 6.69 (-0.28)
Amicus Therapeutics Announces Second Quarter 2016 Financial Results and Corporate Updates
GlobeNewswire - Tue Aug 09, 6:31AM CDT
Significant Progress with EU Galafold Launch and Regulatory Submissions
FOLD: 6.69 (-0.28)
Amicus Therapeutics to Submit Japanese New Drug Application for Migalastat for Fabry Disease in 1H17
GlobeNewswire - Wed Aug 03, 6:30AM CDT
Pre-Submission Meeting Completed with Pharmaceuticals and Medical Devices Agency (PMDA) in Japan
FOLD: 6.69 (-0.28)
Amicus Therapeutics to Announce Second Quarter 2016 Financial Results on August 9, 2016
GlobeNewswire - Mon Aug 01, 3:02PM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, August 9, 2016 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2016.
FOLD: 6.69 (-0.28)
Dr. Ron Nardi Joins viDA Therapeutics Science Advisory Board
CNW Group - Wed Jun 15, 9:59AM CDT
viDA Therapeutics, Inc. (viDA) announced today that Dr. Ron Nardi has been appointed to the Science Advisory Board (SAB).
FOLD: 6.69 (-0.28)
Amicus Therapeutics Appoints Craig A. Wheeler to Board of Directors
GlobeNewswire - Fri Jun 10, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced the election and appointment of Craig A. Wheeler to its Board of Directors, effective immediately. In addition, Amicus announced that John F. Crowley, Margaret G. McGlynn, Michael G. Raab, and Glenn P. Sblendorio were re-elected at the 2016 Annual Meeting of Stockholders.
FOLD: 6.69 (-0.28)
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the election of Bradley Campbell to the Company's Board of Directors. Mr. Campbell brings to Progenics extensive experience in the biopharmaceutical industry, with particular expertise in the areas of corporate strategy, commercial operations and planning, business development and sales and marketing. He currently serves as President and Chief Operating Officer of Amicus Therapeutics, a biotechnology company focused on the development of therapies for a broad range of rare and orphan diseases.
PGNX: 6.28 (-0.16), FOLD: 6.69 (-0.28)
Amicus Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
GlobeNewswire - Wed Jun 01, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the Goldman Sachs 37 Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 7, 2016 at 2:40 p.m. PT.
FOLD: 6.69 (-0.28)
Amicus Therapeutics Announces European Commission Approval for Galafold(TM) (Migalastat) in Patients with Fabry Disease in European Union
GlobeNewswire - Tue May 31, 6:30AM CDT
Launch has Begun in Germany
FOLD: 6.69 (-0.28)
Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Thu May 05, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV on Wednesday, May 11, 2016 at 4:20 p.m. PT.
FOLD: 6.69 (-0.28)
Amicus Therapeutics reports 1Q loss
Automated Insights - Tue May 03, 7:01AM CDT
CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Tuesday reported a loss of $43.7 million in its first quarter.
FOLD: 6.69 (-0.28)
Amicus Therapeutics Announces First Quarter 2016 Financial Results and Corporate Updates
GlobeNewswire - Tue May 03, 6:00AM CDT
Positive CHMP Opinion for Broad Label of Migalastat for Fabry Disease in Patients with Amenable Mutations
FOLD: 6.69 (-0.28)
Merck (MRK) Q1 Earnings: Can the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:12AM CDT
Will Merck (MRK) maintain its impressive track record and deliver a positive earnings surprise this quarter as well?
MRK: 62.79 (+0.08), BIND: 0.78 (-0.09), CHMA: 2.47 (-0.07), FOLD: 6.69 (-0.28)
Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:09AM CDT
Will Ligand (LGND) pull a surprise and surpass expectations in the first quarter as well?
LGND: 103.31 (-1.00), SPPI: 5.31 (-0.19), BIND: 0.78 (-0.09), FOLD: 6.69 (-0.28)
Amicus Therapeutics to Announce First Quarter 2016 Financial Results on May 3, 2016
GlobeNewswire - Tue Apr 26, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, May 3, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2016.
FOLD: 6.69 (-0.28)
Amicus Therapeutics Set to Possibly Rebound After Yesterday's Selloff of 2.00%
Comtex SmarTrend(R) - Fri Apr 15, 3:41PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $7.76 to a high of $8.00. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $7.83 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
FOLD: 6.69 (-0.28)
What Caused Amicus Therapeutics Shares To Skyrocket 23% Last Month
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 12, 3:41PM CDT
SOURCE: AMICUS THERAPEUTICS What: After reporting additional late stage trial data and ahead of learning that a key European advisory committee had voted in support of its lead drug, shares of Amicus Therapeutics shot 23.4% higher in March,...
SHPG: 187.18 (-3.04), FOLD: 6.69 (-0.28)
22.5% Return Seen to Date on SmarTrend Amicus Therapeutics Call (FOLD)
Comtex SmarTrend(R) - Mon Apr 04, 12:44PM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 22nd, 2016 at $7.08. In approximately 1 month, Amicus Therapeutics has returned 22.46% as of today's recent price of $8.67.
FOLD: 6.69 (-0.28)
Amicus Therapeutics to Highlight Fabry Disease Program at Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
GlobeNewswire - Wed Aug 31, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that 7 posters highlighting its Fabry program will be included in the Society for the Study of Inborn Errors of Metabolism's 2016 SSIEM Annual Symposium to be held September 6-9, 2016 in Rome, Italy.
FOLD: 6.69 (-0.28)
UPDATE -- New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease
GlobeNewswire - Wed Aug 10, 5:05PM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 011 (FACETS) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat in individuals with Fabry disease were published in the August 11 issue of the New England Journal of Medicine (NEJM). A copy of the manuscript can be found here and in the Science & Technology section of the Amicus Therapeutics corporate website at www.amicusrx.com.
FOLD: 6.69 (-0.28)
New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease
GlobeNewswire - Wed Aug 10, 4:18PM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 011 (FACETS) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat in individuals with Fabry disease were published in the June 9 issue of the New England Journal of Medicine (NEJM). A copy of the manuscript can be found here and in the Science & Technology section of the Amicus Therapeutics corporate website at www.amicusrx.com.
FOLD: 6.69 (-0.28)
Amicus Therapeutics Announces Second Quarter 2016 Financial Results and Corporate Updates
GlobeNewswire - Tue Aug 09, 6:31AM CDT
Significant Progress with EU Galafold Launch and Regulatory Submissions
FOLD: 6.69 (-0.28)
Amicus Therapeutics to Submit Japanese New Drug Application for Migalastat for Fabry Disease in 1H17
GlobeNewswire - Wed Aug 03, 6:30AM CDT
Pre-Submission Meeting Completed with Pharmaceuticals and Medical Devices Agency (PMDA) in Japan
FOLD: 6.69 (-0.28)
Amicus Therapeutics to Announce Second Quarter 2016 Financial Results on August 9, 2016
GlobeNewswire - Mon Aug 01, 3:02PM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, August 9, 2016 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2016.
FOLD: 6.69 (-0.28)
Dr. Ron Nardi Joins viDA Therapeutics Science Advisory Board
CNW Group - Wed Jun 15, 9:59AM CDT
viDA Therapeutics, Inc. (viDA) announced today that Dr. Ron Nardi has been appointed to the Science Advisory Board (SAB).
FOLD: 6.69 (-0.28)
Amicus Therapeutics Appoints Craig A. Wheeler to Board of Directors
GlobeNewswire - Fri Jun 10, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced the election and appointment of Craig A. Wheeler to its Board of Directors, effective immediately. In addition, Amicus announced that John F. Crowley, Margaret G. McGlynn, Michael G. Raab, and Glenn P. Sblendorio were re-elected at the 2016 Annual Meeting of Stockholders.
FOLD: 6.69 (-0.28)
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the election of Bradley Campbell to the Company's Board of Directors. Mr. Campbell brings to Progenics extensive experience in the biopharmaceutical industry, with particular expertise in the areas of corporate strategy, commercial operations and planning, business development and sales and marketing. He currently serves as President and Chief Operating Officer of Amicus Therapeutics, a biotechnology company focused on the development of therapies for a broad range of rare and orphan diseases. PGNX: 6.28 (-0.16), FOLD: 6.69 (-0.28)
Amicus Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
GlobeNewswire - Wed Jun 01, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the Goldman Sachs 37 Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 7, 2016 at 2:40 p.m. PT.
FOLD: 6.69 (-0.28)
Amicus Therapeutics Announces European Commission Approval for Galafold(TM) (Migalastat) in Patients with Fabry Disease in European Union
GlobeNewswire - Tue May 31, 6:30AM CDT
Launch has Begun in Germany
FOLD: 6.69 (-0.28)
Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Thu May 05, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV on Wednesday, May 11, 2016 at 4:20 p.m. PT.
FOLD: 6.69 (-0.28)
Amicus Therapeutics reports 1Q loss
Automated Insights - Tue May 03, 7:01AM CDT
CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Tuesday reported a loss of $43.7 million in its first quarter.
FOLD: 6.69 (-0.28)
Amicus Therapeutics Announces First Quarter 2016 Financial Results and Corporate Updates
GlobeNewswire - Tue May 03, 6:00AM CDT
Positive CHMP Opinion for Broad Label of Migalastat for Fabry Disease in Patients with Amenable Mutations
FOLD: 6.69 (-0.28)
Merck (MRK) Q1 Earnings: Can the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:12AM CDT
Will Merck (MRK) maintain its impressive track record and deliver a positive earnings surprise this quarter as well?
MRK: 62.79 (+0.08), BIND: 0.78 (-0.09), CHMA: 2.47 (-0.07), FOLD: 6.69 (-0.28)
Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:09AM CDT
Will Ligand (LGND) pull a surprise and surpass expectations in the first quarter as well?
LGND: 103.31 (-1.00), SPPI: 5.31 (-0.19), BIND: 0.78 (-0.09), FOLD: 6.69 (-0.28)
Amicus Therapeutics to Announce First Quarter 2016 Financial Results on May 3, 2016
GlobeNewswire - Tue Apr 26, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, May 3, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2016.
FOLD: 6.69 (-0.28)
Amicus Therapeutics Set to Possibly Rebound After Yesterday's Selloff of 2.00%
Comtex SmarTrend(R) - Fri Apr 15, 3:41PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $7.76 to a high of $8.00. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $7.83 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
FOLD: 6.69 (-0.28)
What Caused Amicus Therapeutics Shares To Skyrocket 23% Last Month
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 12, 3:41PM CDT
SOURCE: AMICUS THERAPEUTICS What: After reporting additional late stage trial data and ahead of learning that a key European advisory committee had voted in support of its lead drug, shares of Amicus Therapeutics shot 23.4% higher in March,...
SHPG: 187.18 (-3.04), FOLD: 6.69 (-0.28)
22.5% Return Seen to Date on SmarTrend Amicus Therapeutics Call (FOLD)
Comtex SmarTrend(R) - Mon Apr 04, 12:44PM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 22nd, 2016 at $7.08. In approximately 1 month, Amicus Therapeutics has returned 22.46% as of today's recent price of $8.67.
FOLD: 6.69 (-0.28)
